DOCSLIB.ORG

Tarek I. Hassanein, MD

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tarek I. Hassanein, MD CURRICULUM VITAE Tarek I. Hassanein, M.D. Business Address: 131 Orange Avenue, Suite 101, Coronado CA 92118 Phone: 619-990-1698 Email: [email protected] Date of Birth: 07/13/57 EDUCATION: 1975-1976 Alexandria University, Alexandria, Egypt, Pre-Medicine 1976-1982 Alexandria University, Alexandria, Egypt, M.B.,Ch.B with honors 1984-1987 Alexandria University, Alexandria, Egypt, Master of Science/Internal Medicine 1989- ECFMG 1989- FLEX (PA) 1992- American Board of Internal Medicine, Diplomat 1993- American Board of Gastroenterology, Diplomat 2006- American Board of lnternal Medicine, Transplant Hepatology, Diplomat POST- GRADUATE TRAINING: 1992-1994 University of Pittsburgh, Pittsburgh, PA, Fellow GI/Hepatology 1990-1992 Wayne State University, Detroit, MI, Resident, Internal Medicine, PGY II-III 1988-1990 University of Pittsburgh, Pittsburgh, PA, Research Fellow, GI/Hepatology 1984-1987 Alexandria University, Alexandria, Egypt Resident, Internal Medicine, PGY I-III 1983-1984 Military Service, Cairo, Egypt, Internship, Neonatology and Pediatrics 1982-1983 Alexandria University, Alexandria, Egypt, Internship CURRENT POSITION: 2009 - Medical Director Southern California GI & Liver Centers 2009 - Director Southern California Research Center Coronado, CA 2009- Professor of Medicine, School of Medicine University of California San Diego San Diego CA Medical Director 2009- Gastroenterology Services & Comprehensive Liver Care Services Sharp Coronado Hospital Coronado, CA Page 1 Hassanein, Tarek 2014 - Director of Outreach Services for Liver Transplantation University of California San Diego San Diego, CA 2009-2014 Associate Director of Liver Transplantation Scripps Green Hospital, La Jolla, CA 1998-2010 Director of Liver Clinical Trials Center UCSD Medical Center, San Diego, CA 2005-2009 Professor of Clinical Medicine & Surgery School of Medicine, University of California San Diego, San Diego, CA 1997-2009 Medical Director, UCSD Liver Transplantation 2004-2009 Chief of Specialized Liver Cancer Unit Moore’s Cancer Center, UCSD, San Diego, CA CLINICAL APPOINTMENTS: 2009- Medical Director Southern California Liver Centers Coronado, CA 2008-2009 Medical Director, UCSD Liver Transplantation Program Director, Liver Clinical Trials Center University of California San Diego Medical Center, San Diego, CA 1996-2009 Chief of Specialized Liver Cancer Unit Moore’s Cancer Center, UCSD, San Diego, CA 1997-2008 Chief of Clinical Hepatology Director, UCSD Liver Center Medical Director, UCSD Liver Transplantation Program University of California San Diego Medical Center, San Diego, CA 1995–1997 Chief of Hepatology and Transplant Gastroenterology Loma Linda University Medical Center, Loma Linda, CA 1994-1995 Assistant Chief of Transplant Medicine Oklahoma Transplantation Institute Baptist Medical Center of Oklahoma, Oklahoma City, OK Page 2 Hassanein, Tarek ACADEMIC APPOINTMENTS: 2009- Professor of Medicine School of Medicine University of California San Diego, San Diego, CA 2005-2009 Professor of Clinical Medicine and Surgery School of Medicine University of California San Diego, San Diego, CA 1997-2005 Associate Professor of Clinical Medicine and Surgery School of Medicine University of California San Diego, San Diego, CA 1995-1997 Associate Professor of Medicine School of Medicine Loma Linda University, Loma Linda, CA 1994.1995 Visiting Research Associate Pittsburgh Transplantation Institute University of Pittsburgh, Pittsburgh, PA 1987–1988 Assistant Lecturer School of Medicine Alexandria University, Alexandria, Egypt AWARDS AND HONORS: 2014 American Liver Foundation Achievement Award 2011 United States Senate Certificate of Commendation (Dianne Feinstein) 2011 Certificate of Special Congressional Recognition (Brian P. Bilbray) 2011 Certificate of Special Congressional Recognition (Susan A. Davis) 2011 State of California Senate Certificate of Recognition (Mark Wyland) 2011 ALF Combined Health Agencies Health Hero Award 2009 Fellow, American Gastroenterological Association 2005-2006 Professional Development of Future Physicians Award, UCSD 2000 Life member of the National Registry of Who’s Who in the 2000 edition. 1999 “My Boss is a Patriot” Award, United States Naval Reserves 1998 Fellow of American College of Gastroenterology 1997 Fellow, American College of Physicians 1994 ACG/Astra Merck Group Senior Fellow Award 1990 4th Annual Glaxo Fellow Travel Award 1987.1988 Peace-Fellowship Award, US Agency of International Development 1979.1981 Academic Achievement Award, Alexandria University 1975-1976 Academic Achievement Award, Alexandria University Page 3 Hassanein, Tarek CERTIFICATION AND LICENSURE: Physician License, State of California, #A54452 Physician License, Egypt Physician Assistant Supervisor State of California, #SA30942 American Board of Gastroenterology, Diplomat #146759, 1993-2023 American Board of Internal Medicine, Diplomat #146759, 1992-2022 American Board of Internal Medicine, Diplomat, Transplant Hepatology, 2006-2026 ECFMG #415-413-4, 1989 FLEX (PA) #570713015, 1989 MEMBERSHIPS: • American Medical Association • American College of Physicians • American College of Gastroenterology • American Gastroenterological Association • American Association of the Study of Liver Disease • European Association for the Study of the Liver • American Society of Transplant Physicians • National Arab American Medical Association • International Liver Transplantation Society • International Gastro-Surgical Club • Gastroenterology Research Group • San Diego County Medical Society • San Diego Gastroenterology Society • American Liver Foundation San Diego Chapter • California Medical Association EDITORIAL BOARD: • Editorial Board, Liver Transplantation, Past Member • Editorial Board, Hepatology and Gastroenterology, Active Member • Regional Editor, Hepato-Gastroenterology, Past Member • Editorial Board, Digestive Diseases & Sciences, Active Member • Arab Journal of Gastroenterology, International Advisory Board, Active Member • Egyptian Liver Cancer Association, International Advisory Board, Active Member REVIEWER: • Hepatology • Journal of Hepatology • Gastroenterology • American Journal of Gastroenterology • Digestive Diseases and Sciences • Mayo Clinic Proceedings Page 4 Hassanein, Tarek • Journal of Medical Virology • Medical Principles and Practice • Cancer Investigation • Oncology • International Neuropsychological Society • Alimentary Pharmacology & Therapeutics ADVISORY BOARDS/DEVELOPMENT MEETINGS: 1. Faculty 2000 HCV Advisory Board, Roche Laboratories, September 5, 1997. 2. Roferon-A Hepatitis C Advisory Board, Roche Laboratories, January 21, 1998. 3. 1998 Ribavirin Investigators Meeting, Schering, January 29, 1998. 4. Management of Interferon Treatment Failures in Chronic Hepatitis C Roundtable Meeting, Postgraduate Institute for Medicine, March 2, 1998. 5. VPA-985 Investigator Meeting, Wyeth-Ayerst, April 6, 1998. 6. Clinician's Companion II Development Meeting on Hepatitis C, Projects in Knowledge, June 18, 1998. 7. Roundtable Workshop, Management of Interferon Treatment Failures in Chronic Hepatitis C, Dallas TX, 1998. 8. 1999 Rebetron Investigators Meeting, Schering, February 4, 1999. 9. Pegasys Advisory Board, Roche Laboratories, March 19, 1999. 10. Clinician's Companion III Development Meeting on Hepatitis C, June 19, 1999. 11. California Hepatitis C Coalition, 2000 12. Task Force to Develop Strategic Plan for California for Hepatitis C, 2000. 13. SHINE, February, 2000. 14. 2nd Annual Pegasys Global Investigators Event, London, Roche Laboratories, May 3-6, 2001. 15. GI/Hepatology Advisory Board, Beverly Hills CA, November 20, 2001. 16. Pegasys National Advisory Board, Roche Laboratories, March 1-3, 2002. 17. Pegasys Advisory Board, Roche Laboratories, April 6, 2002. 18. Ortho Biotech HCV Regional Ad Board, Symbiotix, August 9, 2002. 19. Consultant, Schering, September 1, 2002-August 31, 2003. 20. GI/Hepatology Regional Advisory Board, Roche Laboratories, March 7-9, 2003. 21. Hepatitis C Advisory Board Meeting, Amgen, Santa Monica CA, November 21-22,2003. 22. Outcomes Research Advisory Board, Roche Laboratories, November 23-24, 2003. 23. Steering Committee, Clinical Research Network in Nonalcoholic Steatohepatitis (NASH/CRN), January 29-30, 2004. 24. AGHC-002 Investigators Meeting, Intermune, March 12-14, 2004. 25. HCV Joint MD/NP/PA Regional Advisory Board, April 23, 2004. 26. Amgen Hepatitis C Advisory Board, Marina Del Rey CA, May 1, 2004. 27. Steering Committee, Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), Intermune, June 2004. 28. Hepatology National Advisory Board, Intermune, June 4-6, 2004. 29. Schering Corporation Advisory Board, Schering, July 15-16, 2004. 30. PEGASYS National Advisory Board, Roche Laboratories, August, 2004. 31. Roche Laboratories Advisory Board, September 2004. 32. Intermune Steering Committee, December 2004. 33. AMA CME Hepatitis C Advisory Board, 2005. Page 5 Hassanein, Tarek 34. InterMune Hepatology Regional Advisory Board, April, 2005. 35. Prospectives in Hepatitis C Outcomes: An Educational Network for Improving Options in Treatment Failures (PHOENIX) Advisory Board. 36. Member, Scientific Interest Group, “NeuroAIDS Therapeutics & Comorbidities: Clinical & Laboratory Markers” for the Neuromedical Core of the HIV Neurobehavioral Research Center (HNRC), UCSD Medical School. 37. PEGASYS Speakers Bureau Training, May, 2005. 38. Viramidine Advisory Board, May 2006. 39. Schering Fatigue Advisory Board, June 2006. 40. Roche Counter-IDEAL Advisory Board, August 2006. 41. Valeant
Load more

Recommended publications
  • Magnetic Anastomosis Rings to Create Portacaval Shunt in a Canine Model of Portal Hypertension
    Journal of Gastrointestinal Surgery (2019) 23:218 4–2192 https://doi.org/10.1007/s11605-018-3888-5 ORIGINAL ARTICLE Magnetic Anastomosis Rings to Create Portacaval Shunt in a Canine Model of Portal Hypertension Hao-Hua Wang1,2,3 & Jia Ma4 & Shan-Pei Wang1,2,3 & Feng Ma2,3 & Jian-Wen Lu1,2,3 & Xiang-Hua Xu1,2,3 & Yi Lv1,2,3 & Xiao-Peng Yan 1,2,3 Received: 16 May 2018 /Accepted: 15 July 2018/Published online: 21Aug ust2018 # 2018 The Society for Surgery of the Alimentary Tract Abstract Purpose This study evaluated a novel magnetic compression technique (magnamosis) for creating a portacaval shunt in a canine model of portal hypertension, relative to traditional manual suture. Methods Portal hypertension was induced in 18 dogs by partial ligation of the portal vein (baseline). Six weeks later, extrahepatic portacaval shunt implantation was performed with either magnetic anastomosis rings, or traditional manual suture (n =9,each). The two groups were compared for operative time, portal vein pressure, and serum biochemical indices. Twenty-four weeks post- implantation, the established anastomoses were evaluated by color Doppler imaging, venography, and gross and microscopic histological examinations. Results Anastomotic leakage did not occur in either group. The operative time to complete the anastomosis for magnamosis (4.12 ± 1.04 min) was significantly less than that needed for manual suture (24.47 ± 4.89 min, P < 0.01). The portal vein pressure in the magnamosis group was more stable than that in the manual suture group. The blood ammonia level at the end of the 24- week post-implantation observation period was significantly lower in the magnamosis group than in the manual suture group.
    [Show full text]
  • Chapter 48 Portal-Systemic( Shunting for Metabolic Disease Thomas E
    ----.. ~--. Chapter 48 Portal-Systemic( Shunting for Metabolic Disease Thomas E. Star;l, Kendrick A. Porter and Shun;aburo lwatsuki MECHANISM Of PORTAL DIVERSION EffECTS 1329 GLYCOGEN STORAGE DISEASE (GSD) 1331 Metabolic effects 1331 Growth 1333 Encephalopathy and other risks 1334 The present status of portal diversion 1335 FAMILIAL HYPERCHOLESTEROLAEMIA (FH) 1335 Effect upon serum lipids 1335 Experience of others in treating FH 1335 Morbidity 1335 Effect upon cardiovascular disease 1336 Limitations of portacaval shunt 1337 ALPHA-I-ANTITRYPSIN DEFICIENCY 1337 SUMMARY 1338 REFERENCES 1338 For many years portal venous diversion has main splanchnic venous 'hepatotrophic' factors been used for the haemodynamic objectives of are almost certainly endogenous hormones of stopping or preventing haemorrhage from oeso­ which the single most important is insulin. De­ phageal varices or. less commonly. to treat in­ privation of the liver of the so-called hepato­ tractable ascites. Since 1963. a new dimension trophic effects of portal blood has been noted has been added to the old operation of porta­ under several experimental conditions (includ­ caval shunt by employing this procedure to ing portacaval shunt) to cause hepatocyte atro­ alter favourably the course of three inborn er­ phy. deglycogenation and fatty infiltration. rors of metabolism: glycogen storage disease. With electron microscopic studies. relatively hyperlipoproteinaemia and alpha-I-antitrypsin specific findings have been disruption and re­ deficiency. In this chapter we will discuss the duction of the rough endoplasmic reticulum results and the potential postoperative risks of (RER) and diminution of its lining polyribo­ portal diversion for these new indications. as somes. B . 32. J7. 38. J9.
    [Show full text]
  • Effect of Portal Venous Blood Flow Diversion on Portal Pressure
    Effect of Portal Venous Blood Flow Diversion on Portal Pressure DAVID S. ZIMMON and RICHARD E. KESSLER, Medical Service, Gastroenterology Section and the Surgical Service, New York Veterans Administration Medical Center, and the New York University School of Medicine, New York 10010 A B S T R A C T To anticipate the hepatic vascular re- for as long as 9 yr (median survival 4.0 yr). The 13 sponse to portacaval anastomosis, we studied portal patients who developed chronic encephalopathy had pressure during diversion of portal blood through a significantly lower pressure (21.1+4.4 cm, mean+SD) temporary extracorporeal umbilical vein to saphenous and shorter survival (median 0.6 yr) than the other 27 vein shunt. The relationship of portal pressure to patients (32.6± 5.3 cm, 5.0 yr). The preoperative estima- shunted flow was approximately linear. In five schisto- tion of portal pressure-diverted portal flow curve slope somiasis patients (controls) portal diversion to 1,250 anticipates the hepatic vascular response to portacaval ml/min gave portal pressure-shunted flow curve slopes anastomosis and identifies a group of patients in whom ranging from 0.13 to 0.57 cm water/100 ml per min loss of portal blood flow results in a low residual (0.31±0.18, mean+SD). In 17 cirrhotic patients with intrahepatic venous pressure that is associated with portal hypertension a continuum of slopes was observed early death and chronic encephalopathy. from within mean±2 SD of control (type A) to larger slopes (type B) indicating failure of portal pressure reg- INTRODUCTION ulation.
    [Show full text]
  • Cholesterol Homeostasis in the Rat with a Portacaval Anastomosis
    Proc. Natt. Acad. Sci. USA Vol. 76, No. 9, pp. 4654-4657, September 1979 Medical Sciences Cholesterol homeostasis in the rat with a portacaval anastomosis (sterol balance/hydroxymethylglutaryl-CoA reductase/tissue deposition/bile acid synthesis) ALAN PROIA*, DONALD J. MCNAMARA*, K. DAVID G. EDWARDSt, AND E. H. AHRENS, JR.*t *The Rockefeller University and tCornell University Medical College/Memorial Sloan-Kettering Cancer Center, New York, New York 10021 Contributed by Edward H. Ahrens, Jr., June 18, 1979 ABSTRACT Studies were undertaken to determine the ef- (11-13). Normal body growth is essential to the proper inter- fect of portacaval anastomosis on cholesterol homeostasis in rats pretation of sterol balance data and of enzyme activities, a fed sucrose/lard under conditions of normal body growth. Four met in most of the studies thus to 6 weeks after portacaval shunt surgery, we found decreases prerequisite that has not been in plasma cholesterol and triglyceride concentrations, total liver far reported (8, 14, 15). Our results support the original hy- weight, and hepatic microsomal protein concentration. Mea- pothesis of Starzl et al. (3) that, in the rat, PCA results in de- surements of hepatic 3-hydroxy-3-methylglutaryl-coenzyme A creases in specific activities and total liver activities of hepatic (HMG-CoA) reductase (EC 1.1.1.34) activity showed decreases HMG-CoA reductase as well as decreased rates of whole body in specific activity and total liver activity in portacaval shunt cholesterol synthesis as measured by sterol balance methods. rats, but the enzyme diurnal rhythm remained. Decreased re- ductase activity in shunted rats was not due to an altered Km for D-HMG-CoA, nor was an enzyme inhibitor found in the MATERIALS AND METHODS livers of the portacaval shunt animals.
    [Show full text]
  • Topic 12. Arteries of Lower Extremity. 1. a Patient Has the Ischemia of Tissues Below the Knee-Joint Accompanied by Intermittent Claudication
    Topic 12. Arteries of lower extremity. 1. A patient has the ischemia of tissues below the knee-joint accompanied by intermittent claudication. Which artery occlusion is meant? A. Popliteal. B. Femoral. C. Posterior tibial. D. Anterior tibial. E. Proximal part of femoral artery. 2. While examining a patient, a surgeon detects artery pulsation behind medial malleolus. Which artery is meant? A. Posterior tibial. B. Fibular. C. Anterior tibial. D. Posterior recurrent tibial. E. Anterior recurrent tibial. 3. A 45-year-old patient's skin of the right foot and leg is pale; there is pulsations of the dorsal artery of foot and posterior tibial artery. Pulsation of the femoral artery is preserved. Which artery is damaged? A. Descending genicular. B. External iliac. C. Fibular. D. Deep artery of thigh. E. Popliteal. 4. Examining blood supply a doctor detects pulsation of a large artery, which passes ahead of the talocrural joint between the tendons of the long extensor of the big toe and the long extensor of fingers in a separate fibrous canal. Which artery is this? A. A. tarsea lateralis. B. A. tibialis posterior. C. A. tarsea medialis. D. A. dorsalis pedis. E. A. fibularis. 5. Examining blood supply of a foot a doctor detects pulsation of a large artery behind the malleolus medialis in a separate fibrous canal. Which artery is this? A. A. dorsalis pedis. B. A. tibialis posterior. C. A. tibialis anterior. D. A. fibularis. E. A. malleolaris medialis. 6. After resection of the middle third of a femoral artery, obstructed by a clot, a lower extremity is supplied with blood due to collateral anastomoses.
    [Show full text]
  • Selection of Appropriate Tumour Data Sets for Benchmark
    Food and Chemical Toxicology xxx (2013) xxx–xxx Contents lists available at ScienceDirect Food and Chemical Toxicology journal homepage: www.elsevier.com/locate/foodchemtox Selection of appropriate tumour data sets for Benchmark Dose Modelling (BMD) and derivation of a Margin of Exposure (MoE) for substances that are genotoxic and carcinogenic: Considerations of biological relevance of tumour type, data quality and uncertainty assessment Lutz Edler a, Andy Hart b, Peter Greaves c, Philip Carthew d, Myriam Coulet e, Alan Boobis f, ⇑ Gary M. Williams g, Benjamin Smith h, a German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany b The Food and Environment Research Agency – FERA, Sand Hutton, YO41 1LZ York, United Kingdom c Department of Cancer Studies and Molecular Medicine, University of Leicester, LE2 7LX Leicester, United Kingdom d Unilever, Colworth House Sharnbrook, MK44 1LQ Bedfordshire, United Kingdom e Nestlé Research Centre, Vers-Chez-Les-Blanc, 1000 Lausanne, Switzerland f Imperial College, Hammersmith Campus, Ducane Road, W12 0NN London, United Kingdom g New York Medical College, Basic Science Building, Room 413, Valhalla, NY 10595, United States h Firmenich, Rue de la Bergere 7, 1217-Meyrin 2, Switzerland article info abstract Article history: This article addresses a number of concepts related to the selection and modelling of carcinogenicity data Available online xxxx for the calculation of a Margin of Exposure. It follows up on the recommendations put forward by the International Life Sciences Institute – European branch in 2010 on the application of the Margin of Expo- Keywords: sure (MoE) approach to substances in food that are genotoxic and carcinogenic.
    [Show full text]
  • SURGICAL TREATMENT of PORTAL HYPERTENSION by A
    474 Postgrad Med J: first published as 10.1136/pgmj.32.372.474 on 1 October 1956. Downloaded from SURGICAL TREATMENT OF PORTAL HYPERTENSION By A. I. S. MACPHERSON, CH.M., F.R.C.S.E. Surgeon, Royal Infirmary, Edinburgh; Lecturer, Department of Surgery, University of Edinburgh When the flow of portal blood into or through anterior abdominal wall (' caput Medusae') or the liver is gradually obstructed the hydrostatic demonstrated as ' oesophageal varices' by oeso- pressure in the portal system of veins rises, the phagoscopy or radiography after barium swallow. spleen enlarges and a collateral venous circulation (5) In more than 80% of cases the obstruction is develops to return the portal blood to the general within the liver, secondary to chronic hepatic circulation. This syndrome is given the name of disease, and symptoms and signs of such a condi- Portal Hypertension. The site of the obstructing tion are also evident. lesion may be inside or outside the liver. Intra- hepatic obstruction is almost invariably caused by Indications for Surgical Treatment cirrhosis of the liver, the regeneration of the The prime indication for surgical treatment in parenchyma and the growth of fibrous tissue portal hypertension is the occurrence of haema- which constitute the "healing" phase of this temesis or melaena. Operation may also be called condition a distortion of the vascular for when an is and causing gross enlarged spleen causing pain Protected by copyright. tree and greatly increasing the resistance to portal discomfort as well as persistent gi'anulopenia and blood flow through it. Extra-hepatic obstructions thrombocytopenia or to prevent the onset of may be situated in the portal vein itself, in which severe bleeding when oesophageal varices can be case the hypertension and other changes affect demonstrated and other features of the syndrome the whole portal bed but the liver is normal, or are present.
    [Show full text]
  • Thrombosis of the Portal Vein with Recanalization in Hepatic Cirrhosis
    THROMBOSIS OF THE PORTAL VEIN WITH RECANALIZATION IN HEPATIC CIRRHOSIS CHARLES H. BROWN, M.D., Department of Gastroenterology RICHARD C. BRITTON, M.D.,* Department of General Surgery FRED F. WHITCOMB, JR., M.D.,f and RASIM TURKSEL, M.D.t Department of Gastroenterology CUTE thrombosis of the portal vein has been reported as a complication il occurring in from 10 to 20 per cent of patients with cirrhosis of the liver.1"9 Symptoms and findings vary in relation to the type of onset of thrombosis and to the stage of hepatic disease. Although the complication is relatively rare, the true incidence is difficult to determine because diagnosis usually is not made with certainty before the death of the patient. The dual purpose of this paper is to report thè case of a patient with hepatic cirrhosis in whom an acute portal vein thrombosis developed, proved by means of splenoportography both before and after recanalization, and to describe the nature of the symptoms that initially led us to suspect this diagnosis. Report of a Case A 39-year-old man was admitted to the hospital in November, 1959, because of anorexia, bloating, and intermittent cramping in the region of the umbilicus, of one year's duration. The abdominal pain had increased during the month before admission, having been so severe as to have awakened the patient at night several times. Three weeks before admission, jaundice without itching, tremulousness, and abdominal distention developed, and the urine became dark. The patient reported having consumed five or six highballs daily during the past 10 years, but there was no previous history of jaundice, hepatic disease, or ingestion of chlorpromazine hydrochloride.
    [Show full text]
  • Selected Abstracts
    Selected Abstracts Pages with reference to book, From 194 To 196 Patients' Reactions to Their Investigations. C. Hawkins (Queen Elizabeth Hosp, Birmingham, England) Br. Med. T- 2:638-640 (Sept. 15) 1979. Five hundred four patients who had had hospital examinations were interviewed to find out how much information they had been given about the tests; their reactions before, during, and after the test; and any after effects. In 74% of cases the tests had been satisfactorily explained. Patients were told more about complicated procedures, such as cardiac catheterization, than about routine ones, such as venepuncture or barium meal examinations. The comments physicians made while performing the examinations were generally reassuring. About one half of the patients had pain or discomfort during the tests, and more complained of after effects. Only 5% said they would refuse the test again, though 36% said they would agree reluctantly. Hospitals might consider issuing information sheets to support the physician's explanation and to dispel myths. Localization of Gastrinomas by Transhepatic Portal Catheterization and Gastrin Assay. F. Burcharth et al (Herlev Hosp, Herlev Copenhagen, Denmark) Gastroenterology 77:444-450 (Sept.) 1979. Gastrinomas were localized by concurrent blood sampling in the hepatic vein and portal vein tributaries in ten of 12 patients with Zollinger-EIlison syndrome. Six patients were subsequently operated on: five had pancreatoduodenal resection and one had laparotomy at which metastases were found. Four of the resections were probably curative as the patients have done well without treatment since surgery, with concentrations of gastrin in serum near zero. The observation period ranged from 17 to 20 months.
    [Show full text]
  • Pulmonary Hypertension Due to Micro-Thromboembolism from Splenic and Portal Veins After Portacaval Anastomosis
    British Heart_Journal, I970, 32, 269. Pulmonary hypertension due to micro-thromboembolism from splenic and portal veins after portacaval anastomosis M. Sallam and W. C. Watson From the Gastro-intestinal Unit, Glasgow Royal Infirmary This is a presentation of a unique case of pulmonary hypertension in a x5-year-old girl, due to micro-thromboembolism from splenoportal veins through a portacaval anastomosis. Micro-thromboembolism producing insidious It is doubtful if age by itself is an important pulmonary hypertension is an important factor in the aetiology of thromboembolism category of pulmonary embolism. It contrasts (Marshall, I965), though the incidence is par- with other types which, because the emboli ticularly low in children. are larger, present with acute or subacute symptoms. Wood (1956) in his description Case report of subacute thromboembolic pulmonary This is an account of a unique case of pulmonary hypertension stressed the importance of early hypertension secondary to thromboembolism diagnosis and treatment with anticoagulants. arising in the portal and splenic veins of a I5- Goodwin (I960) pointed out that thrombo- year-old girl, after a portacaval anastomosis. embolism was probably the commonest cause The patient presented at the age of 5 with of obliterative pulmonary vascular disease. haematemesis and melaena from oesophageal He and his colleagues (Goodwin, Harrison, varices. She had hepatosplenomegaly, and the and Wilcken, I963) classified patients with diagnosis of Banti's syndrome was made. She chronic pulmonary hypertension of embolic continued to have episodes of acute alimentary into two those with bleeding, until at the age of 9 a portacaval origin groups, large anastomosis was performed. At operation the emboli affecting main or segmental arteries, distal half of the portal vein was seen to be vari- and others with small emboli affecting micro- cosed and thrombosed, and there was some loose scopic vessels leading to progressive oblitera- clot.
    [Show full text]
  • Chronic Liver Failure: Mechanisms and Management (Clinical
    CLINICAL GASTROENTEROLOGY Series Editor George Y. Wu University of Connecticut Health Center, Farmington, CT, USA For further volumes: http://www.springer.com/series/7672 Chronic Liver Failure MECHANISMS AND MANAGEMENT Edited by PERE GINÈS Liver Unit, Hospital Clinic University of Barcelona, Barcelona, Spain PATRICK S. KAMATH Division of Gastroenterology and Hepatology Mayo Clinic, College of Medicine Rochester, MN, USA VICENTE ARROYO Liver Unit, Hospital Clinic University of Barcelona, Barcelona, Spain Editors Pere Ginès, MD Patrick S. Kamath, MD Liver Unit Division of Gastroenterology and Hepatol Hospital Clinic College of Medicine University of Barcelona Mayo Clinic Villarroel 170 200 First St. S.W 08036 Barcelona, Spain Rochester, MN 55905, USA [email protected] [email protected] Vicente Arroyo Liver Unit Hospital Clinic University of Barcelona Villarroel 170 08036 Barcelona, Spain [email protected] ISBN 978-1-60761-865-2 e-ISBN 978-1-60761-866-9 DOI 10.1007/978-1-60761-866-9 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 201093895 © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.
    [Show full text]
  • Volume 09, Index Canadian Medical Association
    Western University Scholarship@Western Canadian Journal of Surgery 10-31-1966 Volume 09, index Canadian Medical Association Follow this and additional works at: https://ir.lib.uwo.ca/cjs Part of the Surgery Commons Recommended Citation Canadian Medical Association, "Volume 09, index" (1966). Canadian Journal of Surgery. 45. https://ir.lib.uwo.ca/cjs/45 This Book is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Canadian Journal of Surgery by an authorized administrator of Scholarship@Western. For more information, please contact [email protected], [email protected]. The Canadian Journal of Surgery Le journal canadien de chirurgie VOLUME 9 JANUARY 1966 — OCTOBER 1966 Chairman, Editorial Board: Dr. F. G. Kergin Editor, C.M.A. Publications: Dr. G. T. Dickinson Associate Editor, C.M.A. Publications: Dr. J. O. Godden No. 1 January 1966 ................................Pages 1 -124 No. 2 April 1966 ............................................ 125-212 No. 3 July 1966 213-324 No. 4 October 1966 ...................................... 325-460 published by The Canadian Medical Association 150 St. George Street, Toronto, Ont. 2 THE CANADIAN JOURNAL OF SURGERY Vol. 9 valve replacement: clinical experience in 70 INDEX TO VOLUME 9 cases [Cohen and others] 131. APPARATUS AND INSTRUMENTS: See Equip­ A ment and Supplies. ABDOMEN, Responses of gastroesophageal junc­ APPENDECTOMY, Intussusception complicating tional zone to increases in abdominal pressure appendectomy: case report; case [O’Brien] [Lind, Warrian and Wankling] 32. 278. ABDOMINAL INJURIES, Blunt abdominal trau­ ARSENAULT, L.: See Turcot, J., jt. auth. ma ( E ) 445. ARTERIES, Superficial arteries of cubital fossa Blunt abdominal trauma [Maobeth] 384.
    [Show full text]